Literature DB >> 17157779

Peripheral sympathetic component of the temporomandibular joint inflammatory pain in rats.

Luciane Lacerda Franco Rocha Rodrigues1, Maria Cláudia Gonçalves Oliveira, Adriana Pelegrini-da-Silva, Maria Cecília Ferraz de Arruda Veiga, Carlos Amílcar Parada, Cláudia Herrera Tambeli.   

Abstract

UNLABELLED: The aim of this study was to further validate our carrageenan-induced temporomandibular joint (TMJ) inflammatory hyperalgesia model in rats by showing that administration of indomethacin before the initiation of inflammation would diminish the TMJ hyperalgesia. Using this model, we investigated whether norepinephrine and local beta-adrenoceptors contribute to the development of inflammatory TMJ hyperalgesia. Carrageenan-induced TMJ hyperalgesia was assessed by measuring the behavioral nociceptive responses, such as rubbing the orofacial region and flinching the head, induced by the injection of a low dose of 5-hydroxytryptamine into the TMJ sensitized 1 h before by a TMJ injection of carrageenan. Blockade of prostaglandin synthesis by indomethacin prior to initiation of inflammation by carrageenan significantly attenuated the TMJ hyperalgesia. The guanethidine depletion of norepinephrine or the blockade of beta(2)but not the blockade of the beta(1)-adrenoceptor by the selective adrenoceptor antagonists ICI 118.55 and atenolol, respectively, significantly reduced carrageenan-induced TMJ hyperalgesia. In the present study, we further validated our carrageenan-induced TMJ hyperalgesia model to study the mechanisms involved in inflammatory TMJ hyperalgesia and to test the analgesic effect of different types of peripheral analgesics. We also demonstrated that norepinephrine released at the site of injury contributes to the development of the inflammatory TMJ hyperalgesia by the activation of beta(2)-adrenoceptors. PERSPECTIVE: The findings that local sympathomimetic amines contribute to the inflammatory TMJ hyperalgesia by activating beta(2)-adrenoceptors may be relevant to clinical TMJ inflammatory pain states less sensitive to nonsteroidal anti-inflammatory drugs.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17157779     DOI: 10.1016/j.jpain.2006.05.006

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  11 in total

1.  Adrenergic dysregulation and pain with and without acute beta-blockade in women with fibromyalgia and temporomandibular disorder.

Authors:  Kathleen C Light; Edith E Bragdon; Karen M Grewen; Kimberly A Brownley; Susan S Girdler; William Maixner
Journal:  J Pain       Date:  2009-05       Impact factor: 5.820

2.  Biopsychosocial influence on shoulder pain: Rationale and protocol for a pre-clinical trial.

Authors:  Steven Z George; Roland Staud; Paul A Borsa; Samuel S Wu; Margaret R Wallace; Warren H Greenfield; Lauren N Mackie; Roger B Fillingim
Journal:  Contemp Clin Trials       Date:  2017-03-14       Impact factor: 2.226

3.  Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study.

Authors:  Inna E Tchivileva; Pei Feng Lim; Shad B Smith; Gary D Slade; Luda Diatchenko; Samuel A McLean; William Maixner
Journal:  Pharmacogenet Genomics       Date:  2010-04       Impact factor: 2.089

4.  A cyclic pathway of P2 × 7, bradykinin, and dopamine receptor activation induces a sustained articular hyperalgesia in the knee joint of rats.

Authors:  Juliana Maia Teixeira; Carlos Amílcar Parada; Cláudia Herrera Tambeli
Journal:  Inflamm Res       Date:  2017-12-19       Impact factor: 4.575

5.  COMT Genotype and Efficacy of Propranolol for TMD Pain: A Randomized Trial.

Authors:  G D Slade; R B Fillingim; R Ohrbach; H Hadgraft; J Willis; S J Arbes; I E Tchivileva
Journal:  J Dent Res       Date:  2020-10-08       Impact factor: 6.116

6.  Behavioral testing in rodent models of orofacial neuropathic and inflammatory pain.

Authors:  Agnieszka Krzyzanowska; Carlos Avendaño
Journal:  Brain Behav       Date:  2012-08-15       Impact factor: 2.708

7.  Efficacy and safety of propranolol for treatment of temporomandibular disorder pain: a randomized, placebo-controlled clinical trial.

Authors:  Inna E Tchivileva; Holly Hadgraft; Pei Feng Lim; Massimiliano Di Giosia; Margarete Ribeiro-Dasilva; John H Campbell; Janet Willis; Robert James; Marcus Herman-Giddens; Roger B Fillingim; Richard Ohrbach; Samuel J Arbes; Gary D Slade
Journal:  Pain       Date:  2020-08       Impact factor: 7.926

Review 8.  Animal Models of Temporomandibular Disorder.

Authors:  Ting Xiang; Zhuo-Ying Tao; Li-Fan Liao; Shuang Wang; Dong-Yuan Cao
Journal:  J Pain Res       Date:  2021-05-26       Impact factor: 3.133

9.  β2-Adrenergic signal transduction plays a detrimental role in subchondral bone loss of temporomandibular joint in osteoarthritis.

Authors:  Kai Jiao; Li-Na Niu; Qi-hong Li; Gao-tong Ren; Chang-ming Zhao; Yun-dong Liu; Franklin R Tay; Mei-qing Wang
Journal:  Sci Rep       Date:  2015-07-29       Impact factor: 4.379

10.  Activation of α2A-adrenergic signal transduction in chondrocytes promotes degenerative remodelling of temporomandibular joint.

Authors:  Kai Jiao; Guang Zeng; Li-Na Niu; Hong-Xu Yang; Gao-Tong Ren; Xin-Yue Xu; Fei-Fei Li; Franklin R Tay; Mei-Qing Wang
Journal:  Sci Rep       Date:  2016-07-25       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.